A Phase 3 interventional study of triptorelin embonate (INN) in Prostatic Neoplasm, sponsored by Debiopharm International SA. Completed at 1 site in South Africa. Open to male participants. Per ClinicalTrials.gov, last updated 2014-07-25.
Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 14th largest by enrollment, is one of 2 that started in 2006, is one of 12 in phase 3, and was the 6th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+ · Men only
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Sites in Spain
Ages 18+
Marco Lorenzo Bonu · Sites in Italy
Ages 18–80 · Men only
By country, each count listing its studies:
triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 13 · Phase 4 6
First in 2002; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 120 across the 28 interventional studies. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Debiopharm International SA, one of the names counted as Debiopharm. Under that name alone:
Debiopharm International SA is the lead sponsor of 51 studies on the registry; 6 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Debiopharm has 3 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing triptorelin in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05851547Ottawa Hospital Research InstituteDose Escalation For INtraprostatic LEsions | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer. It was assumed that during the study treatment >90% of the patients would achieve and maintain castrate levels of serum testosterone.
Efficacy of triptorelin treatment on gonadotropin (LH) stimulation from hypophysis, as well as on the PSA (prostate specific antigen) levels and safety laboratory parameters. The triptorelin pharmacokinetics and testosterone pharmacodynamics were assessed in a subset of 15 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: triptorelin embonate (INN)
Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
Achievement of Castration and Maintenance of Castration
Percentage of patients achieving castrate testosterone levels (≤1.735 nmol/L) by Day 29 (28 days after study drug injection) and percentage of patients maintaining castrate testosterone levels from Month 2 to end of Month 12 (Week 48).
Time frame: at Day 29
LH Increase
% of patients showing ≤1.0 IU/L increase in s-LH from 0 to 2 h after 1st \& 2nd injection.% changes in PSA throughout treatment.% of 60 pts with s-testosterone levels \>1.735 nmol/L after 2nd injection.Testosterone PD and triptorelin PK metrics in 15 pts
Time frame: day 1 and day 169
| Milestone | Triptorelin |
|---|---|
| Started | 120 |
| Completed | 115 |
| Not completed | 5 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Death | 3 |
| Withdrew: Withdrawal by subject | 1 |
Percentage of patients achieving castrate testosterone levels (≤1.735 nmol/L) by Day 29 (28 days after study drug injection) and percentage of patients maintaining castrate testosterone levels from Month 2 to end of Month 12 (Week 48).
| percentage of enrolled patients | Triptorelin |
|---|---|
| Achievement of Castration and Maintenance of Castration | 97.5 |
% of patients showing ≤1.0 IU/L increase in s-LH from 0 to 2 h after 1st \& 2nd injection.% changes in PSA throughout treatment.% of 60 pts with s-testosterone levels \>1.735 nmol/L after 2nd injection.Testosterone PD and triptorelin PK metrics in 15 pts
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Triptorelin | — | 17/120 (14.2%) | 115/120 (95.8%) |
| Event | Triptorelin |
|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/120 |
| Acute myocardial infarctionCardiac disorders | 1/120 |
| Angina pectorisCardiac disorders | 1/120 |
| Atrial flutterCardiac disorders | 1/120 |
| Myocardial infarctionCardiac disorders | 1/120 |
| Diabetes mellitusEndocrine disorders | 1/120 |
| PneumoniaInfections and infestations | 1/120 |
| skin lacerationInjury, poisoning and procedural complications | 1/120 |
| Soft tissue injuryInjury, poisoning and procedural complications | 1/120 |
| Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/120 |
| Event | Triptorelin |
|---|---|
| Hot flushVascular disorders | 87/120 |
| InfluenzaInfections and infestations | 19/120 |
| HypertensionVascular disorders | 17/120 |
| Back painMusculoskeletal and connective tissue disorders | 13/120 |
| Erectile dysfunctionReproductive system and breast disorders | 12/120 |
| Urinary tract infectionRenal and urinary disorders | 11/120 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/120 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 9/120 |
| HeadacheNervous system disorders | 9/120 |
| Testicular atrophyReproductive system and breast disorders | 9/120 |
| Age, Categorical(Participants) | Triptorelin |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 0 |
| >=65 years | 120 |
| Age, Continuous(years) | Triptorelin |
|---|---|
| Mean | 71.11 ± 8.46 |
| Sex: Female, Male(Participants) | Triptorelin |
|---|---|
| Female | 0 |
| Male | 120 |
| Region of Enrollment(participants) | Triptorelin |
|---|---|
| South Africa | 120 |
The record gives a start of Jul 2006, a primary completion of Aug 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 4 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triptorelin